ÀÖÌìÌÃappÏÂÔØ

Overall Benefit Sample Clauses

The Overall Benefit clause defines the requirement that the agreement or arrangement must provide a net positive advantage to one or both parties. In practice, this clause may stipulate that the obligations, services, or deliverables exchanged under the contract must result in a tangible benefit, such as cost savings, improved efficiency, or enhanced value, when considered as a whole. Its core function is to ensure that the parties are not bound to continue with the agreement if the intended overall benefit is not realized, thereby protecting parties from being locked into unfavorable or unproductive arrangements.
Overall Benefit.ÌýThe Grantee certifies that the aggregate use of the Grant funds shall principally benefit persons of low and moderate income in a manner that ensures that at least seventy percent (70%) of the amount is expended for activities that benefit such persons.
Source 1Source 2Source 3See All (5)
Overall Benefit.ÌýThe aggregate use of CDBG funds, including Section 108 guaranteed loans, during program year(s) 2021-2023[a period specified by the grantee of one, two, or three specific consecutive program years], shall principally benefit persons of low and moderate income in a manner that ensures that at least 70 percent of the amount is expended for activities that benefit such persons during the designated period.
Source 1
Overall Benefit.ÌýRisk Conclusion Revised the overall benefit risk conclusion. To clarify benefit-risk assessments based on changes in above sections Section 4.4 End of Study Definition Clarified early termination and end of study definitions. To provide clarity for these definitions Section 5.0 Study Population (Sections 5.1, 5.2, 5.3, 5.4) â€� Revised inclusion and exclusion criteria for all patients. â€� Added eligibility criteria for Groups 1, 2 and 3 â€� Removed inclusion and exclusion criteria that were not applicable To clarify eligibility criteria for the different patient groups Section 6 Study Intervention, Section 6.1 Study Intervention Administered, Section 6.2 Preparation/ Handling/ Storage/ Accountability Added language describing the tablet formulation of the study drug that will be introduced in this study once the tablet formulation becomes available. To incorporate tablet form
Source 1
Overall Benefit.ÌýRisk Conclusionâ€� Considering the severity of the disease, the continuing anemia and reticulocytosis in some patients on C5 inhibitors, and the lack of an effective oral therapy alternative for PNH patients, there is a clear need for new therapies to improve PNH management. ALXN2050 is expected to provide improved efficacy based on its mechanism of action and optimized PK profile. Based on the preclinical and clinical data available to date, the benefit-risk profile remains favorable for advancing the development of ALXN2050 for the treatment of patients with PNH.
Source 1
Overall Benefit.ÌýTo the best of its knowledge, the aggregate use by the entitlement community of CDBG Funds including section 108 guaranteed loans during program year(s) 2010, 2011, 2013 (a period specified by the local government consisting of one, two, or three specific consecutive program years), shall principally benefit persons of low and moderate income in a manner that ensures that at least 70 percent of the amount is expended for activities that benefit such persons during the designated period;
Source 1

Related to Overall Benefit

  • Death Benefit Should Employee die during the term of employment, the Company shall pay to Employee's estate any compensation due through the end of the month in which death occurred.

  • Retirement Benefit (i) In consideration of the Executive's past services to the Company, the Executive shall be entitled to a retirement benefit, payable monthly for his life, in an amount equal to 50 percent of his highest monthly Base Salary during the Employment Term. Such payments shall commence on the first day of the month coincident with or next following the later of the Executive's attainment of age 58 or the end of the Employment Term (the "Commencement Date"); provided, however, that if the Employment Term terminates prior to his attainment of age 58, the Executive may elect by written notice to the Company to have such payments commence on the first day of any month after such termination of employment (the "Early Commencement Date") in a monthly amount equal to the monthly amount that the Executive would have received at the Commencement Date, reduced by one-third of one percent (.33%) per month for each month by which the Early Commencement Date precedes the Commencement Date. The amount of each payment hereunder shall be increased on each January 1 following the Early Commencement Date or Commencement Date, as applicable, by an amount determined by multiplying the amount of each monthly payment made in the preceding year by the percentage increase, if any, in the cost of living from the preceding January 1, as reflected by the Consumer Price Index. The Executive's election to have his retirement benefit payments commence on the Early Commencement Date shall not affect the Company's obligation to pay consulting fees to the Executive in accordance with Section 4 hereof. The retirement benefit shall be an unconditional, but unsecured, general credit obligation of the Company to the Executive, and nothing contained in this Agreement, and no action taken pursuant to it, shall create or be construed to create a trust of any kind between the Company and the Executive. The Executive shall have no right, title or interest whatever in or to any investments which the Company may make (including, but not limited to, an insurance policy on the life of the Executive) to aid it in meeting its obligations hereunder. (ii) From time to time, the Company shall make such contributions to the trust established under the Trust Agreement dated as of December 18, 1986 (the "1986 Trust") between the Company, as grantor, and Wixxxxx X. Xxxxxxxx, as successor trustee, to provide a sufficient reserve for the discharge of its obligation to pay the retirement benefit to the Executive as provided in clause (i) of this Section 3(c) and clauses (ii) and (iii) of Section 5(a) hereof.

  • Public Benefit It is XR's understanding that the commitments it has agreed to herein, and actions to be taken by XR under this Settlement Agreement confer a significant benefit to the general public, as set forth in Code of Civil Procedure § 1021.5 and Cal. Admin. Code tit. 11, § 3201. As such, it is the intent of XR that to the extent any other private party serves a notice and/or initiates an action alleging a violation of Proposition 65 with respect to XR's alleged failure to provide a warning concerning actual or alleged exposure to DEHP prior to use of the Covered Products it has manufactured, distributed, sold, or offered for sale in California, or will manufacture, distribute, sell, or offer for sale in California, such private party action would not confer a significant benefit on the general public as to those Covered Products addressed in this Settlement Agreement, provided that XR is in material compliance with this Settlement Agreement.

  • Exclusive Benefit The foregoing conditions are for the exclusive benefit of the Purchaser and any such condition may be waived in whole or in part by the Purchaser delivering to the Vendor a written waiver to that effect signed by the Purchaser.

  • Normal Retirement Benefit Upon Termination of Employment on or after the Normal Retirement Age for reasons other than death, the Company shall pay to the Executive the benefit described in this Section 2.1 in lieu of any other benefit under this Agreement.